Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Egis Pharmaceuticals PLC

Latest From Egis Pharmaceuticals PLC

EU Demands Pfizer Offload Its Infliximab Biosimilar In Hospira Buy

Pfizer won EU antitrust approval for its plan to buy Hospira after promising to divest certain assets including its own biosimilar version of tumor necrosis factor inhibitor infliximab, to allay competition concerns. Still open are questions about possible buyers and what this means for competitors.

BioPharmaceutical Europe

Biosimilars In Europe: Big Pharma Playing Catch Up In Own Backyard

As South Korea’s Celltrion Healthcare steals a march with more launches of its biosimilar monoclonal antibody infliximab in major countries in Europe, local companies believe it’s not too late to enter the game.

BioPharmaceutical Europe

Celltrion To Launch Biosimilar Remicade in More European Countries

South Korea’s Celltrion has said it will begin selling Remsima, its biosimilar version of Johnson & Johnson‘s Remicade (infliximab) in 12 more European countries beginning February.

BioPharmaceutical Europe

Lessons From The First Biosimilar MAb Launch In Europe

Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.

BioPharmaceutical Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Hungary
  • Parent & Subsidiaries
  • Egis Pharmaceuticals PLC
  • Senior Management
  • István OrbánHodász, Pres.
  • Contact Info
  • Egis Pharmaceuticals PLC
    Phone: (36) 803 5555
    Keresztúri út 30-38
    Budapest, 1106